Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Therapeutic potential of human adipose-derived stem cells in neurological disorders.

Chang KA., Lee JH., Suh YH.

Narrative Review on Stroke Research, Neuroinflammation, published in J Pharmacol Sci (2014) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Pharmacol Sci (2014)
Country
Japan
Reported sample size
—
Source database
PubMed
PMID
25409785
DOI
10.1254/jphs.14R10CP
Citations
40

Abstract (original English)

Stem cell therapy has been noted as a novel strategy to various diseases including neurological disorders such as Alzheimer's disease, Parkinson's disease, stroke, amyotrophic lateral sclerosis, and Huntington's disease that have no effective treatment available to date. The adipose-derived stem cells (ASCs), mesenchymal stem cells (MSCs) isolated from adipose tissue, are well known for their pluripotency with the ability to differentiate into various types of cells and immuno-modulatory property. These biological features make ASCs a promising source for regenerative cell therapy in neurological disorders. Here we discuss the recent progress of regenerative therapies in various neurological disorders utilizing ASCs.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAlzheimer DiseaseAmyotrophic Lateral SclerosisAnimalsCell DifferentiationCell- and Tissue-Based TherapyHumansHuntington DiseaseMiceNervous System Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research